
ProQR Therapeutics NV is a biotechnology business based in the US. ProQR Therapeutics shares (PRQR) are listed on the NASDAQ and all prices are listed in US Dollars. ProQR Therapeutics employs 181 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in ProQR Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PRQR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Our top pick for
Beginners

Our top pick for
Building a portfolio

Our top pick for
Advanced traders

ProQR Therapeutics stock price (NASDAQ: PRQR)
Use our graph to track the performance of PRQR stocks over time.ProQR Therapeutics shares at a glance
Latest market close | $0.79 |
---|---|
52-week range | $0.53 - $9.09 |
50-day moving average | $0.71 |
200-day moving average | $4.18 |
Wall St. target price | $2.39 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.96 |
Buy ProQR Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy ProQR Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
ProQR Therapeutics price performance over time
Historical closes compared with the close of $0.789 from 2022-07-01
1 week (2022-06-28) | -0.50% |
---|---|
1 month (2022-06-01) | N/A |
3 months (2022-04-01) | N/A |
6 months (2022-01-04) | -90.60% |
1 year (2021-07-02) | -87.88% |
---|---|
2 years (2020-07-02) | -86.21% |
3 years (2019-07-05) | 9.23 |
5 years (2017-07-05) | 5 |
ProQR Therapeutics financials
Revenue TTM | $3.6 million |
---|---|
Gross profit TTM | $2.4 million |
Return on assets TTM | -27.51% |
Return on equity TTM | -85.02% |
Profit margin | 0% |
Book value | $1.41 |
Market capitalisation | $55.5 million |
TTM: trailing 12 months
ProQR Therapeutics share dividends
We're not expecting ProQR Therapeutics to pay a dividend over the next 12 months.
ProQR Therapeutics share price volatility
Over the last 12 months, ProQR Therapeutics's shares have ranged in value from as little as $0.53 up to $9.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProQR Therapeutics's is 0.9614. This would suggest that ProQR Therapeutics's shares are less volatile than average (for this exchange).
ProQR Therapeutics overview
ProQR Therapeutics N. V. , a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc. , and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
ProQR Therapeutics in the news
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposium
Frequently asked questions
What percentage of ProQR Therapeutics is owned by insiders or institutions?Currently 7.777% of ProQR Therapeutics shares are held by insiders and 53.088% by institutions. How many people work for ProQR Therapeutics?
Latest data suggests 181 work at ProQR Therapeutics. When does the fiscal year end for ProQR Therapeutics?
ProQR Therapeutics's fiscal year ends in December. Where is ProQR Therapeutics based?
ProQR Therapeutics's address is: Zernikedreef 9, Leiden, Netherlands, 2333 Ck What is ProQR Therapeutics's ISIN number?
ProQR Therapeutics's international securities identification number is: NL0010872495 What is ProQR Therapeutics's CUSIP number?
ProQR Therapeutics's Committee on Uniform Securities Identification Procedures number is: N71542109
More guides on Finder
-
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
-
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
-
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
-
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
-
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
-
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
-
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
-
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert